Here’s Why Neurocrine Biosciences Inc. (NBIX) Crashed on Friday

We recently compiled a list of the 10 Companies Echo Friday’s Market Pessimism. In this article, we are going to take a look at where Neurocrine Biosciences Inc. (NASDAQ:NBIX) stands against the other stocks.

Ten companies were hit hard on Friday as investors digested disappointing earnings performance and dismal outlook guidance for 2025.

The shares’ performance traded in line with Wall Street’s major indices, with the Dow Jones losing 0.99 percent, the S&P 500 falling 0.95 percent, and the tech-heavy Nasdaq diving 1.36 percent.

To come up with Friday’s worst performers, we considered only the stocks with at least $2 billion in market capitalization and $5 million in daily trading volume.

A healthcare professional discussing treatment options for a patient with a neurological disorder.

Neurocrine Biosciences Inc. (NASDAQ:NBIX)

Neurocrine Biosciences Inc. shares dived 18.53 percent on Friday, a third consecutive day, as investors digested the company’s lackluster fourth-quarter earnings performance and conservative outlook guidance for 2025.

In its earnings release, NBIX said net income in the last quarter fell by 30 percent to $103.1 million from the $147.7 million reported in the same period last year, despite revenues increasing by 21.8 percent to $627.7 million from $515.2 million.

Revenues for the full year increased by 24.8 percent to $2.355 billion from $1.887 billion, pushing net income higher by 36.68 percent at $341.3 million versus the $249.7 million registered in 2023.

For this year, NBIX merely reported a conservative outlook, saying full-year net product sales are projected to settle between $2.5 billion and $2.6 billion.

“With a rapidly advancing and growing pipeline and a strong financial profile, we are well positioned to build a leading neuroscience company,” said NBIX CEO Kyle Gano.

READ NEXT: 20 Best AI Stocks To Buy Now and Complete List of 59 AI Companies Under $2 Billion in Market Cap.

Disclosure: None. This article is originally published at Insider Monkey.